SPIROXATRINE manufacturers
- Spiroxatrine
-
- $80.00 / 5mg
-
2026-01-21
- CAS:1054-88-2
- Min. Order:
- Purity: 99.94%
- Supply Ability: 10g
- SPIROXATRINE
-
- $0.10 / 1KG
-
2025-12-24
- CAS:1054-88-2
- Min. Order: 1KG
- Purity: 98.0%
- Supply Ability: 10
|
| | SPIROXATRINE Basic information |
| Product Name: | SPIROXATRINE | | Synonyms: | SPIROXATRINE;R 5188;(+/-)-8-[(2,3-DIHYDRO-1,4-BENZODIOXIN-2-YL)METHYL]-1-PHENYL-1,3,8-TRIAZA-SPIRO[4,5]DECAN-4-ONE;8-[(2,3-DIHYDRO-1,4-BENZODIOXIN-2-YL)METHYL]-1-PHENYL-1,3,8-TRIAZASPIRO[4,5]DECAN-4-ONE;SPIROXATRINE (R 5188) SELECTIVE SEROTONI N 5;R 5188, (±)-8-[(2,3-Dihydro-1,4-benzodioxin-2-yl)methyl]-1-phenyl-1,3,8-triaza-spiro[4,5]decan-4-one;Spiroxatrine (R 5188);8-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one | | CAS: | 1054-88-2 | | MF: | C22H25N3O3 | | MW: | 379.45 | | EINECS: | | | Product Categories: | Serotonin receptor | | Mol File: | 1054-88-2.mol |  |
| | SPIROXATRINE Chemical Properties |
| Melting point | 215.8-218.0 °C | | Boiling point | 602.8±55.0 °C(Predicted) | | density | 1.32±0.1 g/cm3(Predicted) | | storage temp. | Store at RT | | solubility | 0.1 M HCl: moderately soluble | | pka | 15.03±0.20(Predicted) | | form | powder | | color | white |
| | SPIROXATRINE Usage And Synthesis |
| Uses | Spiroxatrine (R 5188) is a SR-1A antagonist. | | Definition | ChEBI: 8-(2,3-dihydro-1,4-benzodioxin-3-ylmethyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one is a member of imidazolidines. | | Biological Activity | 5-HT 1A antagonist. More active and selective than spiperone. Also a very potent α 2C adrenergic receptor antagonist. | | in vivo | Spiroxatrine (1-25 ug for i.p., 5 days) increases hindpaw withdrawal latencies to thermal and mechanical stimulation in the nerve injury rat and Carrageenan (HY-125474)-induced rat inflammation model[3].
Spiroxatrine (4 mg/kg/day for i.p., 5 mins) increases the voluntary oral ethanol intake induced by Fluoxetine (HY-B0102) in the selectively bred alcohol-preferring P line of rats [4]. | Animal Model: | The nerve injury rat model and Carrageenan (HY-125474)-induced rat inflammation model[3] | | Dosage: | 1, 10, 25 ug, 5 days | | Administration: | Intraperitoneal injection (i.p.) | | Result: | Increased hindpaw withdrawal latencies to thermal and mechanical stimulation. |
| Animal Model: | Fluoxetine (HY-B0102) -induced reduction of ethanol Intake by the P Line of rats[4] | | Dosage: | 4 mg/kg/day, 5 mins | | Administration: | Intraperitoneal injection (i.p.) | | Result: | Increased the voluntary oral ethanol intake induced by Fluoxetine (HY-B0102) in the selectively bred alcohol-preferring P line of rats. |
| | IC 50 | α2-adrenergic receptor; 5-HT1A Receptor: 3.94 nM (Ki); 5-HT1B/D Receptor: 224000 nM (Ki); 5-HT2 Receptor: 118.5 nM (Ki) |
| | SPIROXATRINE Preparation Products And Raw materials |
|